ACMSD Antibody (N-term) Blocking Peptide
€363.00
In stock
SKU
AC-BP8954a
Background:
ACMSD is an intermediate in the de novo synthesis pathway of NAD from tryptophan, and has been implicated in the pathogenesis of several neurodegenerative disorders. Quinolinate is derived from alpha-amino-beta-carboxy-muconate-epsilon-semialdehyde (ACMS).ACMSD (ACMS decarboxylase; EC 4.1.1.45) can divert ACMS to a benign catabolite and thus prevent the accumulation of quinolinate from ACMS.
Other Names:
2-amino-3-carboxymuconate-6-semialdehyde decarboxylase, Picolinate carboxylase, ACMSD
Target/Specificity:
The synthetic peptide sequence used to generate the antibody AP8954a was selected from the N-term region of human ACMSD. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.
Gene Name: ACMSD
Gene ID: 130013
Primary Accession: Q8TDX5
Format: Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.
ACMSD is an intermediate in the de novo synthesis pathway of NAD from tryptophan, and has been implicated in the pathogenesis of several neurodegenerative disorders. Quinolinate is derived from alpha-amino-beta-carboxy-muconate-epsilon-semialdehyde (ACMS).ACMSD (ACMS decarboxylase; EC 4.1.1.45) can divert ACMS to a benign catabolite and thus prevent the accumulation of quinolinate from ACMS.
Other Names:
2-amino-3-carboxymuconate-6-semialdehyde decarboxylase, Picolinate carboxylase, ACMSD
Target/Specificity:
The synthetic peptide sequence used to generate the antibody AP8954a was selected from the N-term region of human ACMSD. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.
Gene Name: ACMSD
Gene ID: 130013
Primary Accession: Q8TDX5
Format: Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.
| Is Featured? | No |
|---|
Write Your Own Review